Ruidong Hao

497 total citations
14 papers, 376 citations indexed

About

Ruidong Hao is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, Ruidong Hao has authored 14 papers receiving a total of 376 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Epidemiology and 5 papers in Immunology. Recurrent topics in Ruidong Hao's work include Hepatitis B Virus Studies (6 papers), CAR-T cell therapy research (5 papers) and Hepatitis Viruses Studies and Epidemiology (3 papers). Ruidong Hao is often cited by papers focused on Hepatitis B Virus Studies (6 papers), CAR-T cell therapy research (5 papers) and Hepatitis Viruses Studies and Epidemiology (3 papers). Ruidong Hao collaborates with scholars based in China and United States. Ruidong Hao's co-authors include Deyin Guo, Xing Liu, Yu Chen, Shuliang Chen, Jing He, Dan Liu, Lei Cui, Yuan Wang, Andong Wu and Hafiz Ullah and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ruidong Hao

12 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruidong Hao China	8	186	183	110	82	82	14	376
Chung-Hsin Tseng Taiwan	8	205 1.1×	188 1.0×	87 0.8×	65 0.8×	139 1.7×	8	402
Catherine Sodroski United States	9	164 0.9×	146 0.8×	134 1.2×	59 0.7×	97 1.2×	10	389
Wandi Zhu China	7	134 0.7×	157 0.9×	88 0.8×	66 0.8×	86 1.0×	9	332
Philipp Schult Germany	9	197 1.1×	147 0.8×	133 1.2×	71 0.9×	78 1.0×	13	457
Itsuki Hamamoto Japan	7	145 0.8×	239 1.3×	234 2.1×	75 0.9×	130 1.6×	12	481
Kaitao Zhao China	17	261 1.4×	398 2.2×	238 2.2×	130 1.6×	83 1.0×	38	628
Mohube Betty Maepa South Africa	8	184 1.0×	189 1.0×	101 0.9×	53 0.6×	28 0.3×	22	311
Ye Zheng China	11	200 1.1×	325 1.8×	229 2.1×	92 1.1×	66 0.8×	21	563
Efraín E. Rivera-Serrano United States	11	187 1.0×	68 0.4×	101 0.9×	158 1.9×	97 1.2×	13	420
Aurélie Ducroux Germany	8	173 0.9×	321 1.8×	171 1.6×	75 0.9×	104 1.3×	9	448

Countries citing papers authored by Ruidong Hao

Since Specialization

Citations

This map shows the geographic impact of Ruidong Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruidong Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruidong Hao more than expected).

Fields of papers citing papers by Ruidong Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruidong Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruidong Hao. The network helps show where Ruidong Hao may publish in the future.

Co-authorship network of co-authors of Ruidong Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Ruidong Hao. A scholar is included among the top collaborators of Ruidong Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruidong Hao. Ruidong Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Zhang, Shuangshuang, et al.. (2025). IMV101, a novel CD19-targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinical models. Blood. 146(Supplement 1). 5875–5875.

Fang, Weijia, Zhengmao Lu, Jing Ge, et al.. (2025). Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer. Molecular Therapy. 33(11). 5516–5529. 1 indexed citations

Sun, Minmin, Hongye Wang, Xin Liu, et al.. (2025). Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor. Cellular Oncology. 48(5). 1299–1315. 1 indexed citations

Lu, Zhengmao, et al.. (2024). Outstanding safety and efficacy data of IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e16012–e16012. 1 indexed citations

Fang, Weijia, et al.. (2024). Efficacy of EpCAM CAR-T IMC001 in advanced gastric cancers.. Journal of Clinical Oncology. 42(16_suppl). 4043–4043. 2 indexed citations

Hao, Ruidong, et al.. (2023). Peri Cruiser CAR-T: An innovative platform to reduce on-target off-tumor toxicity of CAR-T therapy.. Journal of Clinical Oncology. 41(16_suppl). 2539–2539. 2 indexed citations

Wang, Dan, Yang Zhou, Ruidong Hao, et al.. (2023). Yolk precursor synthesis and deposition in hierarchical follicles and effect on egg production performance of hens. Poultry Science. 102(7). 102756–102756. 10 indexed citations

Sajid, Muhammad, Hafiz Ullah, Kun Yan, et al.. (2021). The Functional and Antiviral Activity of Interferon Alpha-Inducible IFI6 Against Hepatitis B Virus Replication and Gene Expression. Frontiers in Immunology. 12. 634937–634937. 39 indexed citations

Ullah, Hafiz, Muhammad Sajid, Kun Yan, et al.. (2021). Antiviral Activity of Interferon Alpha-Inducible Protein 27 Against Hepatitis B Virus Gene Expression and Replication. Frontiers in Microbiology. 12. 656353–656353. 23 indexed citations

10.

Liu, Dan, Lei Cui, Yuan Wang, et al.. (2016). Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity. Hepatology. 64(2). 390–404. 43 indexed citations

11.

He, Jing, Ruidong Hao, Xing Liu, et al.. (2016). Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway. Journal of General Virology. 97(12). 3368–3378. 48 indexed citations

12.

Hao, Ruidong, Jing He, Xing Liu, et al.. (2015). Inhibition of Hepatitis B Virus Gene Expression and Replication by Hepatocyte Nuclear Factor 6. Journal of Virology. 89(8). 4345–4355. 33 indexed citations

13.

Liu, Xing, Ruidong Hao, Shuliang Chen, Deyin Guo, & Yu Chen. (2015). Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. Journal of General Virology. 96(8). 2252–2261. 128 indexed citations

14.

Liu, Dan, Andong Wu, Lei Cui, et al.. (2014). Hepatitis B Virus Polymerase Suppresses NF-κB Signaling by Inhibiting the Activity of IKKs via Interaction with Hsp90β. PLoS ONE. 9(3). e91658–e91658. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact